Boston University’s National Emerging Infectious Diseases Laboratories (NEIDL) to perform independent tests that would assess the ability of the nanosponges to block viral infectivity.

Based upon the current knowledge of SARS-CoV-2, there are two nanosponge i.e. human lung epithelial type II cell nanosponge (denoted “Epithelial-NS”) and human macrophage nanosponge (denoted “MΦ-NS”).”